Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 14/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841319 | 1.00 | SMYD3 (0.52) | SMYD3HPGDPBKCRHR1NPC1 | |
| Hydrochloric Acid SCHEMBL6063550 | 0.99 | SMYD3 (0.51) | SMYD3HPGDPBKCRHR1NPC1 | |
| SCHEMBL5778937 | 0.88 | HPGD (0.51) | HPGDCRHR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5778940 | 0.88 | HPGD (0.51) | HPGDCRHR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8353042 | 0.88 | HPGD (0.51) | SMYD3HPGDCRHR1NPC1RAB9A | |
| SCHEMBL8352231 | 0.87 | HPGD (0.50) | HPGDCRHR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3174715 | 0.86 | NPC1 (0.58) | HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5819954 | 0.86 | HPGD (0.49) | HPGDCRHR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8296522 | 0.85 | HPGD (0.48) | SMYD3HPGDPBKNPC1RAB9A | |
| SCHEMBL6063963 | 0.83 | HPGD (0.46) | HPGDCRHR1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141586-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | CBR3, CBR1, PDE9A | SMYD3 2801/4885HPGD 170/4885PBK 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.